In HCS Pharma, we have already talked about Artificial Intelligence (AI) and the way it is useful in picture analysis. AI can obviously be used for many endeavours, like the shortening of drug discovery timeline as it is explained in the article “Deep learning enables rapid identification of potent DDR1 kinase inhibitors” and in the great review of MIT Technology Review entitled “AI is reinventing the way we invent“.

in silico

Honestly, we do not believe in a complete in silico way to find and test a new drug, at least at the moment. Computer simulations of cells are far from efficient, and the interactions between body elements are much more complex to simulate than a plane with millions parts! “Digital Twin” is a good concept for industries but not for a virtual patient … for the moment 🙂

As described in the article, AI represents an amazing support in the first phases of drug discovery, when we need to choose between millions of molecules to find the most promising drug, against a precise disease. AI is able to find his way through billions of billions compound geometries or in hundred thousand publications about compounds activities. This part of the process, the “design”, will be easier and faster than previously done, and many companies already have products to proposelike Atomwise or Insilico Medicine.

Organ-on-a-chip technology using BIOMIMESYS®

The next step, of course, is to test in vitro the most promising compounds as fast as possible before the costly preclinical tests in vivo . HCS Pharma expertise is complementary to in silico methods:

  • we work in vitro with physiological 3D conditions using BIOMIMESYS® (to simulate in vivo situation and be as predictive as possible)
  • we use High Content Screening (to be fast). Soon, we will be able to go further by using organ-on-a-chip technology and be involved in personalized medicine!

Wish to combine in silico and innovative in vitro technologies? Contact us 🙂

Some articles to understand the topic:

Featured Photo by on Unsplash

Grégory MAUBON

Grégory MAUBON is Chief Data Officer and digital coordinator at HCS Pharma, a biotech startup focused in high content screening and complex diseases. He manages IT missions and leads digital usages linked to company needs. He is also a Augmented Reality Evangelist (presenter and lecturer) since 2008, where he created and founded in 2010 RA'pro (the augmented reality promotion association). He helped many companies (in several domains) to define precisely their augmented reality needs and supported them in the implementation.


Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.